Karachi: Curexa Health (Private) Limited has scheduled its Annual General Meeting for April 30, 2026, where shareholders will address crucial resolutions concerning related party transactions. These transactions, detailed in Note 49 of the financial statements, pertain to dealings with subsidiaries and associates, including Curexa Health (Private) Limited and Route 2 Health (Private) Limited.

During the fiscal year 2025, Curexa Health (Private) Limited reported sales to its wholly-owned subsidiary amounting to 526.61 million rupees, while purchases reached 231.74 million rupees. Furthermore, the company earned a royalty income of 4.49 million rupees, and sales of fixed assets totaled 38.32 million rupees. Payments and receipts during the year were recorded at 25.56 million rupees and 220.86 million rupees, respectively. The company also extended a loan of 425 million rupees to its subsidiary, receiving loan interest of 7.59 million rupees.

According to information available from the Pakistan Stock Exchange (PSX), Route 2 Health (Private) Limited, an associate with common directorship, recorded purchases totaling 115.30 million rupees, while sales were not conducted. The company reported a moderate move in dividend declared at 9.52 million rupees, reflecting a 0.45% change, the same as the previous year.

Pharmatec Investments Limited, another associate, declared and paid dividends amounting to 176.65 million rupees, with significant divergence from the previous year’s payments. Contributions to staff retirement funds and welfare trusts were also notable, with payments reaching 88.37 million rupees for retirement benefit plans and 3.69 million rupees to staff welfare trusts.

The AGM will consider approving these transactions and modifications to ensure compliance with Section 207 and/or 208 of the Companies Act 2017. Shareholders will evaluate the financial dealings and their alignment with regulatory standards, aiming to maintain transparency and adherence to corporate governance practices.